Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is anyone familiar w/or looking at ACAD?
Not in but would be interested in other's take on it. Major pop late Jan. on a Cramer pump and just won't die. I never mind shorting Cramer's crap after about 3-5 days but this one is defying gravity so far in anticipation of trail results. TIA
S
Off Topic - Has anyone been looking at ACAD?
never posted here but enjoy reading posts by y'all while I nurse GNBT. No ACAD boards of good use and if off topic discussions are out of bounds, I understand.
Not in ACAD but would be interested in other's take on it. Major pop late Jan. on a Cramer pump and just won't die. I never mind shorting Cramer's crap after about 3-5 days but this one is defying gravity so far. TIA
S
Off Topic - Has anyone been looking at ACAD?
Not in but would be interested in other's take on it. Major pop late Jan. on a Cramer pump and just won't die. I never mind shorting Cramer's crap after about 3-5 days but this one is defying gravity so far. TIA
S
lol, agreed but INSM and SIRI could give it a great run for the $$.
glta
s
Any link between Thorp's Hedge fines and the recent subpeona issued to Cramer, Greenburg and Co. TIA
s
CNBC covering fda panel decision now
but only muddying waters by presenting only Levin's take on issue of "patient rights, harmful drugs". He's been strongly against bringing tysabri back to mkt. Total BS
Has anything really changed?
Since my entry last fall in INSM I try to continually ask myself that question as the company reports on or experiences new events. We comb over each event searching for some greater or lesser meaning yet one thing continues to jump out at me...
Lazard's 12/13 upgrade: ...We arrive at our new 12-month price target of $4.00 price by applying a 5.6 enterprise value-to-revenue multiple to our new 2008 iPlex sales estimate of $119 M, discounted two years at 25%, including fully diluted shares of 109.5 million, which assumes a financing in 2006 Risks to our thesis include a delayed launch for iPlex or faster-than-anticipated launch of Increlex.
Nope, nothing's changed on the financing front. We hashed over their call for 100M fully diluted shares and eventually concluded that was going to happen by 2Q, then the company's filings confirmed it. Lazard has "called the ball".
Now, what has changed, imho?
1. the number of folks that own and/or follow INSM. It's too bad that the noise we're hearing is from those that are daytraders and absolute amateurs in biotech investing. They're pissed they got caught chasing other amateurs and they're all left to call each other names in an effort to placate their mistaken entry "strategy" and biotech experience. I do think that anyone who chased and bought, even those at $3.30 will be handsomely rewarded...if they're still around.
2. the science has been validated for Iplex w/ FDA and it's audience of medical profesionals has also increased as we are no longer excited soley about it's intended use but for applications w/ larger patient pools and for wider worldwide use.
I suggested last week this was beginning to look like an orchestrated series of corporate events and see it unfolding not as we on the outside were anticipating, guessing or pontificating BUT as an pretty well organized effort by a company executing their grand plan. I will use this as a buying opp, look forward to the next PR fm IR and am patient for INSM to exceed Lazard's tgt.
GLTA and thanks again to those that post here.
CC Rollout and Trials Updates Question
did I hear correctly that further product rollout, trails updates would coinside with upcoming industry/professional meetings and conferences?
which of those listed at the AACE site do y'all fell provide the best opp for future INSM announcements?http://www.aace.com/meetings/calendar/calendar.php
fwiw- i was very encouraged by the CC yday. it was a "just the facts ma'am" presentation and could hear the high degree of confidence in their voices and deliveries. i couldn't help but get the feeling as i listened those guys had cheshire cat grins on their faces and were busting at the seams trying not to let some cat out of the bag. IMHO that was just the start of an orchestrated series of pr's fm ir and others.
TIA and long and strong
Today's News...
1)2005 4Qtr and year end on 3/2
2)8K Item 1.01 Entry Into a Material Definitive Agreement.
Option Amendments
Effective February 15, 2006, Insmed Incorporated (the “Company”) accelerated the vesting of 50,000 shares for Thomas A. Keuer and 25,000 shares for Philip J. Young. These shares relate to the options granted to these individuals on August 10, 2004.
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Effective February 20, 2006, Kevin P. Tully was reappointed as Executive Vice President and Chief Financial Officer (principal financial officer and principal accounting officer) of the Company to serve until his successor is duly designated and has qualified or until his earlier resignation or removal. Michael Duncan will assume the role of Controller and relinquish his responsibilities as principal financial officer and principal accounting officer.
Mr. Tully has returned to the Company after briefly pursuing an interest in working for a privately-held healthcare company. Until his departure in August 2005, he had served as our Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer since April 2005. From January 2002 to April 2005, Mr. Tully served as our Treasurer, Controller, principal financial officer and principal accounting officer. From August 2001 until his election as Treasurer, he served as Senior Director, Finance and Administration. Mr. Tully originally joined the Company in March 2001 as Director of Finance and has over 30 years of experience across Europe and the Americas covering finance, marketing and manufacturing. Prior to joining the Company, Mr. Tully served as Vice President of Finance – Europe, and Vice President, Finance and Administration – Americas for Albright and Wilson Ltd., an international chemical producer. Mr. Tully received his O.N.C. in Business and Administration from St. Helens College in England and is a Certified General Accountant.
In connection with his the commencement of employment, Mr. Tully was granted an option for 215,000 shares of the Company’s common stock. The exercise price for his option grant is the fair market value of the Company’s common stock on the date of grant. This option will become exercisable in four equal installments on February 20, 2006, February 20, 2007, February 20, 2008 and February 20, 2009 if Mr. Tully remains continuously employed by the Company until such date. The options expire on February 20, 2012. The Company also expects to enter into a change of control agreement with Mr. Tully but additional information regarding the terms of his change of control agreement were unavailable as of the date of this filing. Mr. Tully will receive a base salary of $225,000.
I can picture it now....Lehman and Baird analysts have been up all night after listening to the TRCA CC come running into their respective trading floors waving their arms, hair on fire, eyes bloodshot, and yelling TRCA, SELL!SELL!SELL! and the numbnuts who put their clients in TRCA start pounding their screens.....I'm gonna start moving the decimal over one space to the right on all my sell orders, lolololol...it's a scene right out of "Trading Places"
...they then retreat to their desks and quietly start putting their personnal items in an empty copier paper box hoping nobody else will see them slink out.
Form 13 G - Alexandra Global Master Fund filing
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3968903
I absolutely agree with your suggestion that they are Spearheading the sales force in VA. Bio/pharmacuetical sales reps for Iplex would be a rather narrow talent pool and I would suggest that their search is very targeted and they're using outside help(headhunters). Having done that for spell the medical equipment and pharma. desks are very specialized. While this move has rather high upfront expenses( %of salary) there is a snowball effect once you get several good sales positions filled. Those folks are then integral in finding the remainder of the hiring effort.
This is from their website, careers section....notice these postitions are the administrative backbone for a sales staff.
"Insmed understands that its most valuable resource is its employees. We place great value on the unique skills, talents and qualities that each of our employees brings to their job at our company.
We are currently recruiting for the following position(s):
Location: Insmed Corporate Headquarters, Glen Allen, VA
Director of Marketing
Director, Regulatory Affairs
Director, Clinical Operations
Clinical Project Manager
Senior Clinical Research Associate
Clinical Statistical Programmer"
Form SC 13G/a Roth,Michael....Thoughts?
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3960882
TIA and GLTA
S-8 Comments?
Coinz, I'm still on a steep learning curve regarding SEC filings. At your convenience, could you comment on the 2/9 S8 filing for 3.5M shares of common @ 2.975? I read it to be part of their 2000 incentive plan but am still curious about how/when such shares are issued and the possible dillution effect. Thanks for all you do on these boards!
S
INSM - Charting Case Study?
Because there was a lack of news releases since the start of the year I have spent more time w/ charting on INSM...helped in large part by the terrific input here on the subject.
I agree in the absence of pr fm ir the pps has responded and been trading quite technically... while I would bite my lip if we saw a final retest of 2.10 I would certainly find some more dry powder to get more shares.
xoxo, I would like to suggest that we could get that same comfirmation above 2.20 (2.18 - 2.25), what do you think.
THanks and GLTA
S
Bolt - Please Share Your Calculations
Thanks for the generous offer, I know we all would enjoy seeing your calculations...what could be more fun on a friday night :^)
GLTA
s
Nice dig, vrtl! thx
S
Buying Opp?
rstor, I'm in the exact same camp. Got 1st taste of INSM well below $2 and am anxious to add. I plan on schinitzleling a little more here so we don't miss that possibility of upcoming announcements and events and I really don't think we go much lower.
Look at the YTD charts and I see supports at each obvious level tested. When a company doesn't have news the short term traders just feed on themselves using TA for their entry/exits. I don't remember who posted the possibility of backing off to 2.20 as their target but as the warrents/converts appeared to get absorbed without any completion filings, I began to get a little more patient for a better entry. I think we're there. The anticipated reports for eps, business model/plan updates are near, I just don't know how close but it makes very good sense that it'll start before trca gets a word in late next week. Thoughts? TIA
BTW, I enjoy reading your posts throughout ihub.
Thanks again Coinz for creating this great space. The exchange here is truly a learning experience. I've learned more about biotechs and their science here and at several other biotech boards in the last 3 months than in my decade of trading.
GLTA
S
interesting post fm Yahoozoo board, would appreciate feedback as I try to better understand charting. TIA
INSM is bouncing nicely off the 20 DMA, the whole week it has been trading between the 10 and 20DMA, I like to think there is someone using a very disciplined approach here to gather shares.
http://stockcharts.com/def/servlet/SC.web?c=INSM,uu[m,a]daclyyay[da][pb20!b10][v c60][iUb14!La12,26,9]&pref=G
I haven't found anything dramatic about specific news coming from companies at the exebition but here is another possibly useful link(in additon to the one on this site):
http://www.ameinfo.com/news/Event_News/Arab_Health/index.html
s
8K Filing 1/24 :
Item 3.02 Unregistered Sales of Equity Securities
Between January 17, 2006 and January 24, 2006, Insmed Incorporated received notices from holders of its 5.5% Convertible Notes due 2008 - 2010 electing to voluntarily convert $4,175,000 principal amount of Convertible Notes into 3,223,927 shares of common stock at the conversion rate of one share of common stock for each $1.295 in principal amount of the Convertible Notes. The Company also received $3,310,735 from warrant exercises that resulted in 2,434,364 shares of common stock being issued at an exercise price of $1.36. The number of shares issued pursuant to the conversion of the Convertible Notes and exercise of warrants since January 13, 2006, the date of Insmed’s last report under Item 3.02, exceeded 1% of Insmed’s outstanding common stock on January 18, 2006.
The common stock issued upon the conversion of the Convertible Notes and the warrants was issued in reliance upon the exemptions from the registration requirements of the Securities Act of 1933, as amended, provided for in Section 3(a)(9) and Section 4(2) thereof and is all currently registered for resale by the holders pursuant to Insmed’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on August 8, 2005 (the “Registration Statement”).
Following the conversions described above, $6,013,000 principal amount of the Convertible Notes remained outstanding. In addition, because certain of the Convertible Notes were converted prior to the March 1, 2006 quarterly interest payment, the Company issued an additional 24,068 shares of common stock for the forfeited cash interest payment at a conversion price of $1.295. A summary of the terms of the Convertible Notes and the warrants, including the conversion features and interest payments of the Convertible Notes was previously provided in the Registration Statement and Insmed’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2005 (the “Current Report”). The forms of the Convertible Notes and the warrants were filed on a Current Report filed with the SEC on March 16, 2005. The Registration Statement, the Current Report, the forms of the Convertible Notes and warrants are each incorporated herein by reference.
coinz -
Can you elaborate on the addition of TRCA's fmr CFO and it's benefits and/or drawbacks?
While I'm curious about the timing of his departure at TRCA I also applaud it in light of the INSM storyline.
Thanks
I did buy more, thanks
The pps is at levels that introduce a growning number of shorts and judging from their increased venum on several boards they will be here to stay so long as INSM succeeds. With increased exposure we're going to see more of those "traders" on the dark side. Don't many firms limit shorting to stocks above $3 of $5? Could the surge above 3 been a move grab shares to make available to short? Whomever employs them I'd like to think they are attempting to drive the pps down in order to cover and go long at lower price. Thoughts?
Has anyone else noticed that as a whole they are incredibly simplistic in their efforts to attempt to drive the pps down to simple chart supports. With that said does anyone think INSM has enough price support at 2.75? My concern is we lose that next level would be 2.46? TIA
Im long, and excited about INSM long range prospects thanks to many here.
Thanks for putting this together....
Its fantastic...INSM long since 1.56 and looking forward to contributing to our success.